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Purpose: To evaluate safety and efﬁcacy of adalimumab in patients with noninfectious intermediate, pos-
terior, or panuveitis.
Design: Phase 3, open-label, multicenter clinical trial extension (VISUAL III).
Participants: Adults meeting treatment failure (TF) criteria or who completed VISUAL I or II (phase 3, ran-
domized, double-masked, placebo-controlled) without TF.
Methods: Patients received adalimumab 40 mg every other week. Interim follow-up data were described
from VISUAL III weeks 0 through 78.
Main Outcome Measures: Disease quiescence, steroid-free quiescence, active inﬂammatory chorioretinal/
retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, best-corrected visual acuity (BCVA),
and corticosteroid dose. Binary data were reported using nonresponder imputation (NRI), continuous data using
last observation carried forward and as-observed analysis, and corticosteroid dose using observed-case anal-
ysis. Adverse events (AEs) were reported from ﬁrst adalimumab dose in VISUAL III through interim cutoff.
Results: Of 424 patients enrolled, 371 were included in intent-to-treat analysis. At study entry, 242 of 371
(65%) patients had active uveitis; 60% (145/242, NRI) achieved quiescence at week 78, and 66% (95/143, as-
observed) of those were corticosteroid free. At study entry, 129 of 371 (35%) patients had inactive uveitis;
74% (96/129, NRI) achieved quiescence at week 78, and 93% (89/96, as-observed) of those were corticosteroid
free. Inﬂammatory lesions, anterior chamber grade, and vitreous haze grade showed initial improvement followed
by decline in patients with active uveitis and remained stable in patients with inactive uveitis. BCVA improved in
patients with active uveitis from weeks 0 to 78 (0.27 to 0.14 logMAR; left and right eyes; as-observed) and
remained stable in patients with inactive uveitis. Mean corticosteroid dose decreased from 13.6 mg/day (week 0)
to 2.6 mg/day (week 78) in patients with active uveitis and remained stable in those with inactive uveitis (1.5e1.2
mg/day). AEs (424 events/100 patient-years) and serious AEs (16.5 events/100 patient-years) were comparable
with previous VISUAL trials.
Conclusions: Patients with active uveitis at study entry who received adalimumab therapy were likely to
achieve quiescence, improve visual acuity, and reduce their daily uveitis-related systemic corticosteroid use.
Most patients with inactive uveitis at study entry sustained quiescence without a systemic corticosteroid dose
increase. No new safety signals were identiﬁed. Ophthalmology 2018;-:1e13 ª 2018 by theAmericanAcademyof
Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Supplemental material available at www.aaojournal.org.Noninfectious intermediate, posterior, and panuveitis are
uncommon, immune-mediated, inﬂammatory ocular dis-
eases frequently associated with comorbid systemic in-
ﬂammatory conditions.1 Estimates suggest that these
uveitides account for 19% to 40% of cases of
noninfectious uveitis,2e4 with a worldwide prevalence ofª 2018 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.38/100 000 people.5,6 In the United States, the overall
prevalence of noninfectious uveitis among adults is esti-
mated to be 121/100 000 (98/100 000 anterior, 1/100 000
intermediate, 10/100 000 posterior, and 12/100 000 pan-
uveitis).4 Compared with individuals without these
conditions, patients with noninfectious intermediate,1https://doi.org/10.1016/j.ophtha.2017.12.039
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Ophthalmology Volume -, Number -, Month 2018posterior, or panuveitis are estimated to have a 10-fold
increased risk of blindness or low vision,3,7 and cumula-
tive damage caused by recurring uveitis ﬂares can increase
this risk.8 Although corticosteroids are the mainstay of
uveitis treatment, they are associated with common and
potentially serious side effects accompanying long-term
and high-dose use.9e11 Additional therapies would ideally
target speciﬁc mediators of the immune response underlying
uveitic inﬂammation to achieve disease quiescence and
allow reduced corticosteroid burden and related complica-
tions, while providing greater efﬁcacy than conventional
steroid-sparing immunosuppressive agents.12
Tumor necrosis factorea (TNF-a) is a cytokine that con-
tributes to inﬂammation in immune-mediated diseases,
including noninfectious uveitis.9,13,14 The human mono-
clonal antibody to TNF-a, HUMIRA (adalimumab; AbbVie
Inc, North Chicago, IL), blocks the interaction between TNF-
a and its cell surface receptors to inhibit inﬂammatory TNF-a
signaling.15 Adalimumab is approved for the treatment of
several immune-mediated inﬂammatory diseases, including
noninfectious intermediate, posterior, and panuveitis.12,16
The efﬁcacy of adalimumab in managing uveitis was
demonstrated in 2 randomized, double-masked, placebo-
controlled trials of patients with active uveitis despite treat-
ment with high-dose (10e60 mg/day prednisone equivalent)
systemic corticosteroids (VISUAL I)17 or uveitis dependent
on higher than recommended10,18 doses of systemic cortico-
steroids for disease control (10e35 mg/day prednisone
equivalent; VISUAL II).19 In the parent studies, treatment
failure (TF) was assessed and deﬁned by a rigorous
composite end point based on 4 components (new
inﬂammatory chorioretinal and/or inﬂammatory retinal
vascular lesions, anterior chamber cell grade, vitreous haze
grade, and best-corrected visual acuity [BCVA]).17,19 In
these studies, adalimumab effectively reduced the risk of TF
compared with placebo in patients with active or inactive
uveitis.17,19 Furthermore, signiﬁcantly higher rates of quies-
cence (deﬁned as no active inﬂammatory lesions, anterior
chamber cell grade 0.5þ, and vitreous haze grade 0.5þ)
and corticosteroid-free quiescence were achieved and main-
tained through 52weeks in theVISUAL I/II studies in patients
receiving adalimumab compared with placebo, regardless of
disease status at study entry.20
The objective of the open-label extension study, VISUAL
III, was to evaluate the safety and efﬁcacy of extended
adalimumab treatment in patients with noninfectious inter-
mediate, posterior, or panuveitis who successfully completed
the VISUAL I or VISUAL II trials without TF (deﬁned as
patients with inactive uveitis in VISUAL III) or experienced
TF in the parent trials (deﬁned as patients with active uveitis in
VISUAL III). This report describes the interim analysis of
VISUAL III through 78 weeks of follow-up.Methods
Study Design
This was an open-label, multicenter, unmasked, uncontrolled, phase
3 extension study (VISUAL III; registered at www.clinicaltrials.gov,
trial ID NCT01148225 and www.clinicaltrialsregister.eu, EudraCT2number 2009-016196-29) conducted at sites in Argentina, Australia,
Austria, Belgium, Brazil, Canada, the Czech Republic, Denmark,
France, Germany, Greece, Israel, Italy, Japan, Mexico, Poland,
Portugal, Spain, Switzerland, the United Kingdom, and the United
States. Study visits occurred atweek 0 (baseline); at weeks 2, 4, 8, 12,
and 18; and every 12 weeks thereafter. The window for all scheduled
visits was 7 days. The trial extension is ongoing; this report de-
scribes follow-up efﬁcacy and safety data through week 78, as of the
interim cutoff of October 31, 2016. All patients had the opportunity
to reach week 78 before the cutoff date. This interim analysis was
conducted to provide real-world data after approval of adalimumab
to treat uveitis. Efﬁcacy data were collected from the ﬁrst adalimu-
mab dose in VISUAL III through 78 weeks of follow-up. Safety data
were collected from the ﬁrst adalimumab dose in VISUAL III and
until up to 70 days after the last dose of adalimumab or up to the
interim cutoff date of October 31, 2016, whichever occurred ﬁrst.
The study complied with the ethical principles of the Declara-
tion of Helsinki and the International Conference on Harmo-
nisation Guidelines for Good Clinical Practice; sites in the United
States conformed to the requirements of the Health Insurance
Portability and Accountability Act. All patients signed a statement
of informed consent before enrollment, and all procedures were
reviewed and approved by appropriate institutional review boards
or ethics committees before study initiation.
Patients
Eligible patients were aged 18 years and diagnosed with nonin-
fectious intermediate, posterior, or panuveitis. Patients had either
discontinued from a phase 3 parent study (VISUAL I, trial ID
NCT01138657; or VISUAL II, trial ID NCT01124838) for having
met predeﬁned TF criteria or successfully completed the parent
study without TF. Randomization from the parent studies was not
disclosed before entry in VISUAL III. Enrolled patients were
required to complete the VISUAL III baseline visit within 28 days
of the ﬁnal visit of the parent study. Patients who discontinued
from a parent study for any reason other than TF were not eligible
for participation in VISUAL III.
Key ocular exclusion criteria were corneal or lens opacity that
precluded visualization of the fundus or that would likely require
cataract surgery during trial participation; intraocular pressure
25 mmHg requiring 2 glaucoma medications, or having
evidence of glaucomatous optic nerve injury; BCVA worse than
20/200 (Snellen; equivalent to logMAR >1.0 using an Early
Treatment Diabetic Retinopathy Study [ETDRS] chart) in either
eye; proliferative or severe nonproliferative diabetic retinopathy;
neovascular age-related macular degeneration; or abnormality of
the vitreoretinal interface with the potential for macular structural
damage independent of the inﬂammatory process. Nonocular
exclusions included a history of or neurologic symptoms sugges-
tive of central nervous system demyelinating disease; evidence of
dysplasia or history of malignancy (including lymphoma and
leukemia); and treatment with intravenous or oral antibiotics (30
or 14 days before the baseline visit, respectively). Complete
inclusion and exclusion criteria are listed in Table S1 (available at
www.aaojournal.org).
Of 424 patients enrolled and included in the safety data set, 371
were included in the intent-to-treat (ITT) data set (Fig 1). Patients
(n ¼ 53) were excluded from the ITT set if they developed
proliferative or severe nonproliferative diabetic retinopathy or
clinically signiﬁcant macular edema caused by diabetic
retinopathy, underwent cataract surgery during the study, or had
previous vitrectomy or underwent vitrectomy during the study
(i.e., surgeries that could be a reason for a patient’s improvement
in vision other than the study drug). Additional reasons for
exclusion from the ITT set were incomplete efﬁcacy source data
Figure 1. Patient disposition in the VISUAL III study. Patients with
multiple reasons for discontinuation were included in the count for each
reason. *Other reasons for discontinuation included patient relocation,
noncompliance, planned pregnancy, and investigative site stopped
participating in the registry.
Suhler et al  Efﬁcacy and Safety of Adalimumab in VISUAL IIIin the parent study and general compliance issues at the study site
in the parent studies. An additional 5 patients with macular hole or
rhegmatogenous retinal detachment were excluded from analysis
of central subﬁeld thickness (CST).
Treatment
All patients received open-label subcutaneous adalimumab 40 mg
every other week for the duration of the study regardless of
treatment assignment in the parent studies. Patients were allowed,
at the investigator’s clinical discretion throughout the study, to
initiate, continue, escalate, or taper concomitant oral or topical
corticosteroid therapy (all corticosteroids were systemic unless
noted otherwise) and/or any one of the immunosuppressive ther-
apies permitted in the parent study to control intraocular inﬂam-
mation (methotrexate 25 mg/week; cyclosporine 4 mg/kg/day;
mycophenolate mofetil 2 g/day; azathioprine 175 mg/day).
Additionally, patients were allowed 2 periocular corticosteroid
injections per eye per year; intraocular or intravitreal injections
were not allowed.
Outcome Measures
The main outcome measure was quiescence, deﬁned as no active
inﬂammatory chorioretinal and/or inﬂammatory retinal vascular le-
sions (inﬂammatory lesions), anterior chamber cell grade 0.5þ,
and vitreous haze grade 0.5þ in both eyes, similar to the quies-
cence criteria used in the VISUAL I and II trials.17,19 Efﬁcacy vari-
ables included no active inﬂammatory lesions, anterior chamber cell
grade 0.5þ, vitreous haze grade 0.5þ, central retinal thickness,
BCVA, and the dose of uveitis-related corticosteroids andimmunomodulators. There was no designated study eye; outcomes
were evaluated in both eyes at every study visit from weeks
0 through 78.
The absence or presence of new inﬂammatory chorioretinal
and/or inﬂammatory retinal vascular lesions (compared with the
ﬁndings of the ﬁnal visit of the parent study) was determined using
dilated indirect ophthalmoscopy and was based on the in-
vestigators’ clinical judgment. Vitreous haze was evaluated using
dilated indirect ophthalmoscopy and comparison with standard
photographs, as described in the National Eye Institute Criteria
adapted by the Standardization of Uveitis Nomenclature Working
Group (score range, 0 [no vitreous haze] to 4þ [optic nerve head is
obscured]).21,22 Anterior chamber cells (within a 1  1-mm slit
beam) were counted using slit-lamp examination and graded ac-
cording to Standardization of Uveitis Nomenclature Working
Group criteria (score range, 0 [<1 cell in ﬁeld] to 4þ [>50 cells in
ﬁeld]).21 Anterior chamber cell evaluation was performed before
mydriatic eye drops were instilled to dilate the pupil. CST
(center 1-mm subﬁeld) was determined by optical coherence
tomography (OCT) with 1 of 3 instruments: Stratus OCT (Carl
Zeiss Meditec, Inc, Jena, Germany), Cirrus HD-OCT (Carl Zeiss
Meditec, Inc), or Spectralis (Heidelberg Engineering, Heidelberg,
Germany). Each system’s software identiﬁes the internal limiting
membrane as the inner retina. For the outer retinal boundary, the
Stratus OCT uses the ellipsoid zone, the Spectralis uses the Bruch
membrane, and Cirrus HD-OCT uses the inner third of the retinal
pigment epithelium.23,24 BCVA was determined for each eye
separately using appropriate corrective lenses based on patients’
current refraction using a standard ETDRS chart at a distance of 4
or 1 m. BCVA was recorded as the number of letters read and was
transformed into logMAR units for analysis. Dose of uveitis-
related corticosteroids was recorded throughout the study, as
were the doses of other permitted immunosuppressives.
Safety was monitored through adverse event (AE) collection,
physical examination, vital signs, and laboratory testing. AEs were
coded using the Medical Dictionary for Regulatory Activities
(version 19.0). Active or latent tuberculosis was determined by the
investigator.
Statistical Analysis
Efﬁcacy variables were analyzed using data from the ITT data set.
Outcomes were analyzed by uveitis status at baseline (active or
inactive uveitis as deﬁned above) and overall. Binary data were
analyzed descriptively as observed and using the nonresponder
imputation (NRI) method, and exact 95% Clopper-Pearson conﬁ-
dence intervals (CIs) were calculated. Corticosteroid dose and
corticosteroid-free quiescence were summarized descriptively as
observed. BCVA and CST were analyzed descriptively as observed
and using last observation carried forward (LOCF) as the imputation
method; data from left and right eyes were analyzed separately. CST
was analyzed separately for left and right eyes by OCT machine
software. The 95% CI for means and logMAR were calculated.
Analysis of AEs was conducted using the safety data set,
including all patients who received at least 1 dose of adalimumab.
AEs were reported as the total number of events and number of
events per 100 patient-years (PY).
Results
Patients
In the ITT set, 49% of patients (182/371) entered from the
VISUAL I trial and 51% of patients (189/371) entered from the
VISUAL II trial. Most patients were female (58%, 214/371) and3
Table 1. Patient Demographics and Characteristics (Intent-to-Treat Data Set)
Variable Active Uveitis* (N [ 242) Inactive Uveitis* (N [ 129) Total (N [ 371)
Age, y
Mean  SD 42.614.5 42.413.0 42.514.0
Range 19e80 19e81 19e81
Sex, n (%)
Female 135 (56) 79 (61) 214 (58)
Male 107 (44) 50 (39) 157 (42)
Race, n (%)
White 172 (71) 105 (81) 277 (75)
Asian 37 (15) 8 (6) 45 (12)
Black or African American 17 (7) 7 (5) 24 (7)
American Indian or Alaska native 2 (0.8) 0 2 (0.5)
Multiracial 3 (1) 0 3 (0.8)
Other 11 (5) 9 (7) 20 (5)
Type of uveitis, n (%)
Panuveitis 133 (55) 57 (44) 190 (51)
Posterior 52 (22) 52 (40) 104 (28)
Intermediate 55 (23) 19 (15) 74 (20)
Intermediate/posterior 2 (0.8) 1 (0.8) 3 (0.8)
Diagnosis, n (%)
Idiopathic 91 (38) 31 (24) 122 (33)
Vogt-Koyanagi-Harada 48 (20) 24 (19) 72 (19)
Sarcoid 34 (14) 18 (14) 52 (14)
Birdshot choroidopathy 24 (10) 27 (21) 51 (14)
Behçet 11 (5) 16 (12) 27 (7)
Multifocal choroiditis and panuveitis 11 (5) 3 (2) 14 (4)
Other 23 (10) 10 (8) 33 (9)
Duration of uveitis, mo
Mean  SD 63.174.2 62.052.2 62.767.3
Range 2.8e558.4 4.5e260.3 2.8e558.4
Immunomodulator use at baseline, n (%) 67 (28) 54 (42) 121 (33)
Azathioprine 8 (3) 9 (7) 17 (5)
Cyclosporine 12 (5) 13 (10) 25 (7)
Methotrexate 24 (10) 17 (13) 41 (11)
Mycophenolate mofetil or equivalent 23 (10) 15 (12) 38 (10)
Uveitis-related corticosteroid use at baseline, n (%) 142 (59) 9 (7) 151 (41)
Oral 117 (48) 7 (5) 124 (33)
Topical 59 (24) 3 (2) 62 (17)
Other 7 (3) 0 7 (2)
SD ¼ standard deviation.
*Uveitis status at VISUAL III entry. Patients with active uveitis at VISUAL III entry experienced treatment failure in VISUAL I or VISUAL II trials. Patients
with inactive uveitis at VISUAL III entry completed the VISUAL I and VISUAL II trials without experiencing treatment failure.
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(SD) patient age was 42.514.0 years, and the mean duration of
diagnosed uveitis was 62.767.3 months. At study entry, 65%
of patients (242/371) had active uveitis (i.e., experienced TF in
VISUAL I or II) and the remaining 35% (129/371) had inactive
uveitis (i.e., completed the parent trials without experiencing
TF). A total of 121 of 371 (33%) patients were receiving
immunomodulators and 151 of 371 (41%) were receiving
corticosteroids (systemic and nonsystemic) at VISUAL III
baseline; 30 patients (8%) started immunomodulators and 65
patients (18%) started corticosteroids during the study.
Throughout VISUAL III, 33 of 371 (9%) patients received
concomitant local corticosteroid injections.
As of the interim cutoff, 316 patients (75%) were ongoing, and
108 of the 424 patients (25%) in the safety set discontinued the
study before week 78 (Fig 1). Reasons for premature
discontinuation before week 78 were AEs (11%, 48/424), lack of
efﬁcacy (5%, 22/424), withdrawal of consent (2%, 9/424), loss
to follow-up (1%; 5/424), or other reasons (8%, 32/424).4Quiescence
At week 0 of VISUAL III, 93% of patients deﬁned as having
active uveitis (i.e., patients who experienced TF in the parent
trials) were not in quiescence (224/242, NRI). By week 12, 60%
(144/242, NRI) of patients achieved quiescence, which
remained stable at week 78 (60%; 145/242, NRI; Fig 2A).
Of patients who achieved quiescence, 66% were corticosteroid
free (95/143, as observed) at week 78, and 23% were
receiving corticosteroid doses of 7.5 mg/day (33/143, as
observed; Fig 2B).
Of the patients who entered VISUAL III deﬁned as having
inactive uveitis (i.e., patients who completed the parent trials
without experiencing TF), 85% met criteria for quiescence at week
0 (109/129, NRI; Fig 2A). By week 78, the percentage of patients
in quiescence remained stable at 74% (96/129, NRI). Of patients in
quiescence, 96% (105/109, as observed) were not receiving
uveitis-related corticosteroids at week 0, and 93% (89/96, as
observed) were not receiving any corticosteroids at week 78 (Fig
Suhler et al  Efﬁcacy and Safety of Adalimumab in VISUAL III2B). Only 2 patients with inactive uveitis at study entry were
receiving >7.5 mg/day corticosteroids at week 78 to maintain
quiescence.
The trends observed in patients who entered VISUAL III with
active or inactive uveitis were also reﬂected in the overall patient
population (Fig S1A and B, available at www.aaojournal.org).
Quiescence data were also analyzed in patients who were
stratiﬁed by placebo or adalimumab treatment during the parent
VISUAL I and VISUAL II trials. At week 0, 27% of patients who
received placebo (49/185; NRI) and 42% of patients who received
adalimumab (78/186; NRI) during the VISUAL I and II trials were
in quiescence. At week 78, 67% of patients who received placebo
(124/185; NRI) and 63% of patients who received adalimumab
(117/186; NRI) during the VISUAL I and II trials achieved
quiescence (Fig S2A, available at www.aaojournal.org). Of
patients in quiescence, 80% (99/123; as observed) who received
placebo and 73% (85/116; as observed) who received
adalimumab during VISUAL I and II trials were corticosteroid
free at week 78 (Fig S2B, available at www.aaojournal.org).
Other Efﬁcacy Variables
Chorioretinal Lesions. In patients with active uveitis at study
entry, there was an improvement in percentage of patients with no
active chorioretinal lesions, from 64% at week 0 (154/242, NRI) to
83% at week 12 (200/242, NRI), followed by a decline to 69% at
week 78 (166/242, NRI) (Fig 3A).
Anterior Chamber Activity. The percentage of patients with
anterior chamber cell grade  0.5þ in both eyes increased from
50% at week 0 (120/242, NRI) to 81% at week 12 (197/242, NRI),
followed by a decline to 66% at week 78 (159/242, NRI) (Fig 3B).
Vitreous Activity. The percentage of patients with vitreous
haze grade  0.5þ increased from 41% at week 0 (98/242, NRI) to
65% at week 78 (157/242, NRI) (Fig 3C).
In patients with inactive uveitis at study entry in VISUAL III,
the percentage of patients with no active inﬂammatory lesions,
anterior chamber cell grade  0.5þ, and vitreous haze grade
 0.5þ remained stable from week 0 to week 78 (Fig 3).
Efﬁcacy variables in the overall population are described in
Figure S3 (available at www.aaojournal.org).
After a small initial decrease, CST was generally stable
throughout follow-up, regardless of the OCT machine type used
(LOCF; Fig 4AeC). Patients who entered the study with active
uveitis had greater central retinal thickness than those with
inactive uveitis observed with the Stratus OCT and Spectralis.
CST decreased through week 78 in patients with active uveitis
and was generally stable in patients with inactive uveitis. In all
left eyes at week 0, mean CST observed with the Stratus OCT,
Spectralis, and Cirrus HD-OCT was 246.8 mm (n ¼ 105), 321.2 mm
(n ¼ 183), and 302.4 mm (n ¼ 70), respectively, compared with
227.2 mm (n ¼ 72), 295.7 mm (n ¼ 136), and 256.8 mm (n ¼ 56) at
week 78 (as observed). In all right eyes at week 0, mean CST
observed with the Stratus OCT, Spectralis, and Cirrus HD-OCT
was 269.1 mm (n ¼ 105), 311.9 mm (n ¼ 181), and 312.4 mm
(n¼ 71), respectively, compared with 242.6 mm (n¼ 71), 280.5 mm
(n ¼ 135), and 287.9 mm (n ¼ 56) at week 78 (as observed).
For patients with active uveitis, mean change in CST at week 78
from week 8 for the Stratus OCT, Spectralis, and Cirrus HD-OCT
was 14.2 mm (95% CI, 30.5 to 2.1), 7.1 mm (95% CI, 17.7
to 3.5), and 27.0 mm (95% CI, 48.0 to 6.0), respectively, for
the left eyes and 6.4 mm (95% CI, 30.6 to 17.7), 18.3 mm
(95% CI, 30.7 to 5.8), and 1.5 mm (95% CI, 24.0 to 26.9),
respectively, for the right eyes (as observed). For patients with
inactive uveitis, mean change in CST at week 78 from baseline for
the Stratus OCT, Spectralis, and Cirrus HD-OCT was 17.5 mm
(95% CI, 30.8 to 4.1), 0 mm (95% CI, 12.4 to 12.4),and 6.3 mm (95% CI, 16.8 to 4.1), respectively, for the left eyes
and 35.9 mm (95% CI, 75.5 to 3.8), 11.5 mm (95%
CI, 21.5 to 1.5), and 3.1 mm (95% CI, 10.4 to 4.2),
respectively, for the right eyes (as observed).
The percentage of eyes with BCVA < 0.05 logMAR increased
from week 0 (35%) to week 78 (49%) in patients with active uveitis
at study entry but remained stable in eyes with inactive uveitis
(63% and 64% at weeks 0 and 78, respectively; as observed; Fig
5A). Mean BCVA improved over time in patients with active
uveitis at study entry (left eyes: week 0, 0.27 logMAR [n ¼
242], 95% CI, 0.23e0.31; week 78, 0.14 logMAR [n ¼ 175],
95% CI, 0.10e0.18; right eyes: week 0, 0.27 logMAR [n ¼
242], 95% CI, 0.22e0.31; week 78, 0.14 logMAR [n ¼ 175],
95% CI, 0.10e0.19; as observed), whereas mean BCVA
remained stable over time in patients with inactive uveitis (left
eyes: week 0, 0.06 logMAR [n ¼ 129], 95% CI, 0.02e0.10;
week 78, 0.04 logMAR [n ¼ 104], 95% CI, 0e0.09; right eyes:
week 0, 0.05 logMAR [n ¼ 129], 95% CI, 0.01e0.08; week 78,
0.06 logMAR [n ¼ 104], 95% CI, 0.01 to 0.13; as observed;
Fig 5B). Overall, mean BCVA improved in the left eyes from
0.20 logMAR at week 0 (n ¼ 371; 95% CI, 0.16e0.23) to
0.10 logMAR at week 78 (n ¼ 279; 95% CI, 0.07e0.13) and in
the right eyes from 0.19 logMAR at week 0 (n ¼ 371; 95% CI,
0.16e0.22) to 0.11 logMAR at week 78 (n ¼ 279; 95% CI,
0.07e0.15; Fig 5B).
Among patients with active uveitis at study entry, the observed
mean  SD corticosteroid dose was 13.619.1 mg/day at week
0 (n ¼ 237), 6.19.3 mg/day at week 12 (n ¼ 224), and 2.65.2
mg/day at week 78 (n ¼ 173; Fig 6), representing an overall mean
dose reduction of 11.3 mg/day. The observed mean
corticosteroid dose for patients who entered the study with
inactive uveitis was low at baseline, with little change
throughout the follow-up period (week 0, 1.57.2 mg/day [n ¼
128]; week 12, 0.94.1 mg/day [n ¼ 119]; week 78, 1.25.0
mg/day [n ¼ 104]; Fig 6). In the overall population, the observed
mean  SD daily corticosteroid dose was 9.316.9 mg at study
entry (n ¼ 365). The observed mean  SD daily corticosteroid
dose decreased by 75% to 2.15.1 mg at week 78 (n ¼ 277; Fig 6).
The change from baseline was 7.1 (95% CI, 9.2 to 5.1).
Of patients who received immunomodulators at baseline, 78%
with active uveitis at study entry (36/46; 95% CI, 63.6e89.1; as
observed) and 89% with inactive uveitis at study entry (32/36; 95%
CI, 73.9e96.9; as observed) still received immunomodulators at
week 78. However, at week 78 there was a 26%mean decrease in the
dose of immunomodulators compared with week 8 of VISUAL III
for patients with active uveitis at study entry (n¼ 47; 95%CI,39.6
to11.5) and a 15%mean decrease in dose comparedwithweek 0 of
VISUAL III for patients with inactive uveitis at study entry (n¼ 37;
95% CI, 26.1 to 4.7). Additionally, at week 78, 47% of patients
with active uveitis at study entry achieved a 50% reduction in
immunosuppression load (corticosteroids and/or immunomodula-
tors) compared with week 8 (52/110; 95% CI, 37.7e57.0; as
observed), whereas 13% of patients with inactive uveitis at study
entry achieved a 50% reduction in immunosuppression load
(corticosteroids and/or immunomodulators) compared with week
0 (5/39; 95% CI, 4.3e27.4; as observed).
Safety
For all patients enrolled in VISUAL III (N ¼ 424), mean  SD
exposure to adalimumab was 11770 weeks, representing 953.7
PY of exposure. The overall exposure-adjusted rate of any AE was
424 events/100 PY. As summarized in Table 2, there were 82 AEs
leading to study discontinuation (8.6 events/100 PY; Table S2,
available at www.aaojournal.org), 157 serious AEs (16.5 events/
100 PY), of which 36 (3.8 events/100 PY; Table S3, available at5
Figure 2. Percentage of patients achieving quiescence according to disease activity at baseline (A) and according to concomitant dose of steroids (B). Data
are presented as percentage  exact 95% Clopper-Pearson conﬁdence interval (A). Light bars indicate nonresponder imputation analysis (active, n ¼ 242;
inactive, n ¼ 129); dark bars indicate observed-case data with the number of patients observed indicated within the base of the bar. Quiescence was deﬁned
as no active inﬂammatory lesions, anterior chamber cell grade  0.5þ, and vitreous haze grade  0.5þ in both eyes. Doses of uveitis-related systemic
corticosteroids were converted into prednisone equivalents.
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possibly related to adalimumab, and 30 nonserious allergic
reactions (3.2/100 PY). There was a low incidence of active
tuberculosis (0.1 event/100 PY), opportunistic infections (0.5
events/100 PY), serious infections (4.0 events/100 PY), and
malignancies (1.3 events/100 PY). Fifteen patients (1.6 events/
100 PY) described asymptomatic latent tuberculosis based on the
positive ﬁndings of annual tuberculosis testing. The event of
active tuberculosis was considered not related to adalimumab by
the investigator and probably related to adalimumab by the
sponsor. Study drug was discontinued in this patient with active
tuberculosis, and antituberculosis therapy was provided. Five
patients (0.5 events/100 PY) experienced demyelinating
disorders, including multiple sclerosis (n ¼ 1), demyelination
(n ¼ 2; 1 case with magnetic resonance imaging [MRI] was
suggestive of multiple sclerosis), and optic neuritis (n ¼ 2;
neither MRI showed central nervous system ﬁndings of
demyelination). All 5 patients with demyelinating disorders were
discontinued from the study. Two of these patients had
intermediate uveitis, 2 had posterior uveitis, and 1 had
panuveitis. The 1 patient with multiple sclerosis had intermediate6uveitis and was reported to have an abnormal baseline MRI.
Four deaths (0.4 events/100 PY) were reported (1 event each of
metastatic pancreatic carcinoma, brain abscess, B-cell lymphoma
[without ocular involvement], and accidental death). All fatal
events except brain abscess (possibly related) were considered by
the investigator as not related or probably not related to study drug.
Discussion
Effective corticosteroid-sparing therapies are needed to
maintain disease control in eyes with noninfectious inter-
mediate, posterior, and panuveitis and, thereby, to reduce
the risk of visual complications and corticosteroid-related
side effects.
A substantial proportion of patients who entered
VISUAL III with active uveitis (i.e., experienced TF in the
parent studies) were in quiescence at week 78 compared
with baseline (60% vs. 7%, respectively; NRI). By week 78,
two thirds of these patients were in corticosteroid-free
Figure 3. Percentage of patients with active or inactive uveitis at study entry who had no active inﬂammatory lesions (A), anterior chamber cell grade
 0.5þ (B), and vitreous haze grade  0.5þ (C) in both eyes (intent-to-treat data set). Data are presented as percentage  exact 95% Clopper-Pearson
conﬁdence interval. Light bars indicate nonresponder imputation analysis (active uveitis, n ¼ 242; inactive uveitis, n¼ 129); dark bars indicate observed-case
data with the number of patients observed indicated within the base of the bar.
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receiving >7.5 mg/day corticosteroids. The majority of
patients with inactive uveitis (i.e., did not experience TF in
the parent studies) were quiescent at baseline (85%) and the
rate of quiescence remained stable (78%) at week 78, on noor low-dose systemic corticosteroids. It is important to
emphasize that not all patients responded to adalimumab
(40% of patients with active uveitis and 26% of patients
with inactive uveitis were not in quiescence at week 78),
although these results suggest that adalimumab therapy7
Figure 4. Mean central subﬁeld thickness over time in left and right eyes as assessed by optical coherence tomography machine type (intent-to-treat data
set): A, Stratus OCT; B, Spectralis; C, Cirrus HD-OCT. Dashed line indicates last-observation-carried-forward (LOCF) imputation analysis (patient numbers
at week 0 are shown); continuous line indicates observed-case data (patient numbers are indicated below the x-axis). OCT ¼ optical coherence tomography.
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corticosteroid-sparing quiescence. These trends were also
observed in the overall patient population.
Additionally, at least two thirds of patients with active or
inactive uveitis who received adalimumab did not have active
inﬂammatory lesions, had anterior chamber cell and vitreous
haze grades 0.5þ in both eyes, and had stable visual acuity
during weeks 12 to 78 of follow-up. These results are consis-
tent with both the VISUAL I and II trials, in which eyes treated
with adalimumab had a signiﬁcantly reduced risk of recurrence
or worsening of BCVA in patients with uveitis.17,19
Until recently, immunosuppressive medications were
used routinely as steroid-sparing agents10 and were termed
“conventional” despite being used off label for uveitis.
The results of this study conﬁrm and extend the ﬁndings
of early open-label trials in which treatment with adalimu-
mab enabled substantial tapering of immunosuppressive
drugs while achieving disease control in eyes with
corticosteroid-resistant uveitis.25,26
In groups with and without previous exposure to adali-
mumab during the VISUAL I and II trials, the percentage of
patients in quiescence at baseline was numerically greater in8patients who had received adalimumab vs. placebo (42% vs.
27%, respectively). The percentage of patients in quiescence
increased from baseline to week 78 in both groups (adali-
mumab, 42% to 63%; placebo, 27% to 67%; NRI). Of those
in quiescence at week 78, a slightly higher percentage of
patients who had received placebo vs. those who had
received adalimumab in the parent trials were steroid free
(80% vs. 73%, respectively).
In the current open-label study, adalimumab controlled
multiple signs of uveitic inﬂammation (i.e., inﬂammatory
lesions, vitreous haze, anterior chamber cells, and central
retinal thickening) for up to 78 weeks of follow-up in eyes
with active or inactive uveitis at study entry while also
permitting a substantial decrease in systemic corticosteroid
use in patients who enrolled with active uveitis. At week 78,
the as-observed analysis demonstrated that the majority of
patients had anterior chamber cell grade  0.5þ or vitreous
haze grade  0.5þ and no inﬂammatory lesions relative to
baseline. These outcomes were likely reﬂected in the initial
improvement and subsequent long-term stable visual acuity
observed in VISUAL III. Additionally, CST decreased over
time in patients with active uveitis. Because there are
Figure 5. Percentage of eyes with categories of mean logMAR best-corrected visual acuity (BCVA), reported as observed for patients with values at weeks
0 and 78 (A), and BCVA over time, presented as mean  95% conﬁdence interval in left and right eyes (B; intent-to-treat set). Dashed line indicates last-
observation-carried-forward (LOCF) imputation analysis (patient numbers at week 0 are shown); continuous line indicates observed-case data (patient
numbers are indicated below the x-axis).
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Figure 6. Mean daily dose of uveitis-related corticosteroids. Data represent the observed case analysis. Patient numbers are indicated below the x-axis.
Ophthalmology Volume -, Number -, Month 2018differences in how the 3 OCT systems determine CST, we
reported the data separately for each OCT system to control
for differences in software algorithms.
Previous studies have demonstrated that treatment with
adalimumab signiﬁcantly prolongs time to TF (e.g., ﬂare)Table 2. Adverse Events (Safety Data Set)
Events (Events/100 PY)
N [ 424; PY [ 953.7
Any AE 4043 (423.9)
AEs leading to death 4 (0.4)
Accidental death 1 (0.1)
B-cell lymphoma 1 (0.1)
Brain abscess 1 (0.1)
Metastatic pancreatic carcinoma 1 (0.1)
AEs leading to discontinuation 82 (8.6)
Serious AEs 157 (16.5)
Infections 787 (82.5)
Serious infections 38 (4.0)
Opportunistic infections
(excluding oral candidiasis
and tuberculosis)
5 (0.5)
Tuberculosis 16 (1.7)
Active 1 (0.1)
Latent 15 (1.6)
Allergic reactions 30 (3.2)
Malignancies 12 (1.3)
Non-melanoma skin cancer 6 (0.6)
Lymphoma 1 (0.1)
Other* 5 (0.5)
Sarcoidosisy 4 (0.4)
Vasculitisz 8 (0.8)
Liver events including liver failure 10 (1.1)
Demyelinating disorders 5 (0.5)
AE ¼ adverse event; PY ¼ patient-years.
*Adenocarcinoma of colon, colorectal cancer, lobular breast carcinoma in
situ, pancreatic carcinoma, and rectal adenocarcinoma.
yFour events of sarcoidosis were reported by 4 patients, all of whom had
sarcoid uveitis at baseline.
zEight events of vasculitis were reported by 5 patients; 2 patients reported 5
events of Behçet syndrome (1 patient had 1 serious AE leading to pre-
mature discontinuation, and 1 patient reported 4 episodes of Behçet syn-
drome); 3 patients described retinal vasculitis.
10after corticosteroid discontinuation.17,19 However, in clin-
ical practice, patients may receive systemic or topical
corticosteroid support as needed for uveitis control; as such,
corticosteroids were permitted as needed in the current trial.
Patients who enrolled with active uveitis were receiving a
mean corticosteroid dose of nearly 14 mg/day despite rec-
ommendations that prolonged use of doses >10 mg/day be
avoided because of well-characterized systemic side effects,
risk of cataract, and increased intraocular pressure.10,18,27
Adalimumab treatment decreased the mean dose of sys-
temic corticosteroids in these patients by more than 80%, to
<3 mg/day, which is below the commonly accepted clinical
threshold of 5 mg of daily prednisone-equivalent dose.9,10,21
Furthermore, by week 78, only 5% of patients in the overall
study population had discontinued the trial because of a lack
of efﬁcacy.
Treatment with adalimumab was well tolerated in this
study. There was a low incidence of AEs of special interest,
and no new safety signals were detected beyond those pre-
viously reported with biologic therapies targeting TNF-a28,29
and those reported in the VISUAL I and II trials.8,17 The
incidence of demyelinating disorders reported in the
VISUAL III study (0.5/100 PY) was higher than that
observed in clinical trials for other adalimumab indications
(0.1/100 PY). However, the observed rate is comparable to
the background rate reported in patients with uveitis who
were not exposed to adalimumab (Guo D, et al, manuscript in
progress).30 Furthermore, there is a known association
between anterior and intermediate uveitis and
demyelinating disorders31e33; for example, an estimated 7%
to 10% of patients with intermediate uveitis also have mul-
tiple sclerosis.34,35 There were no signiﬁcant changes from
baseline for laboratory tests or vital signs (data not shown).
This study had limitations; because the VISUAL III
study was meant to reﬂect real-life clinical practice, the use
of concomitant immunosuppressants and corticosteroids
was allowed. We hypothesized that adalimumab accounted
for the favorable inﬂammation control observed during the
VISUAL III trial, which occurred in the context of corti-
costeroid tapering, as described previously. However, in the
absence of a control group and in the context of use of other
immunosuppressive agents, drug efﬁcacy cannot be
Suhler et al  Efﬁcacy and Safety of Adalimumab in VISUAL IIIdetermined in comparison with eyes that were not treated
with adalimumab. In addition, there was loss of patient data
over time owing to premature discontinuation. Thus, our
results using the conservative NRI method may underesti-
mate the efﬁcacy of adalimumab observed in a real-world
setting. The true efﬁcacy of adalimumab in patients with
uveitis may lie somewhere between the as-observed analysis
and the analysis imputing nonresponse for patients who
discontinued. Additionally, in patients who entered the
study with inactive uveitis, 15% were not in quiescence at
baseline (i.e., did not meet the criteria of no active inﬂam-
matory lesions, anterior chamber cell grade  0.5þ, and
vitreous haze grade  0.5þ in both eyes); future analyses
will need to address this patient subgroup. Additional
studies are needed to further clarify the long-term efﬁcacy of
adalimumab, including analyses that stratify patients by
response to adalimumab and permit other therapies for the
nonresponder subgroups. Other caveats include inherent
variations among the 3 OCT systems and possible bias in
the LOCF analysis of OCT data; the last available CST
values were assumed to remain constant in missing patients.
This study had several strengths. The patient population
was large, considering that noninfectious uveitis is an un-
common disease, estimated to affect fewer than 0.4% of
people worldwide.5,6 Notably, all patients had the opportu-
nity to complete 78 weeks of follow-up by the interim cutoff
date, October 31, 2016. Further, by allowing the use of
concomitant treatments as needed (corticosteroids and sys-
temic immunomodulators), this study reﬂected a clinically
relevant, real-world approach to uveitis management.
In conclusion, in patients with noninfectious intermediate,
posterior, or panuveitis who received adalimumab (40 mg
every other week), disease was controlled with minimal
corticosteroid support. About two thirds of patients who
entered VISUAL III with active uveitis achieved quiescence
by week 78 with a substantially reduced uveitis-related
corticosteroid dose; additionally, mean BCVA was
improved over time in patients with active uveitis. About
three quarters of patients who entered VISUAL III with
inactive uveitis had maintained quiescence at week 78, with
93% of these patients achieving corticosteroid-free quies-
cence; most patients had stable BCVA throughout follow-up.
Most patients had no active inﬂammatory lesions and had
anterior chamber cell and vitreous haze grades  0.5þ
through 78 weeks of open-label adalimumab treatment,
regardless of active or inactive disease at VISUAL III entry.
The safety proﬁlewas consistentwith the known safety proﬁle
of adalimumab and the underlying disease. These data sug-
gest that adalimumab can be used for intermediate, posterior,
and panuveitis as an important therapeutic option allowing
patients to achieve and maintain long-term disease control
with or without adjunctive corticosteroids or immunomodu-
lators. Longer-term follow-up in VISUAL III is ongoing.References
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